Viatris Inc. (NASDAQ:VTRS) is a global healthcare company that develops, manufactures and commercializes medicines across a broad range of therapeutic areas. Its portfolio includes generic and branded medicines, over-the-counter products, biosimilars and active pharmaceutical ingredients. The company supplies treatments for cardiovascular disease, infectious diseases, central nervous system conditions, immunology, oncology and other areas of healthcare.
Viatris was formed in November 2020 through the combination of Mylan N.V. and Pfizer’s Upjohn business. The transaction brought together Mylan’s generics and biosimilars operations with Upjohn’s established portfolio of off-patent branded medicines. The company also offers manufacturing, regulatory and commercial capabilities intended to support the availability of medicines throughout their product life cycles.
Based in Pittsburgh, Pennsylvania, Viatris serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, emerging markets and other international regions. The company’s global portfolio includes both widely used generic medicines and established brands, allowing it to serve pharmacies, hospitals, distributors and other healthcare customers.
AI Generated. May Contain Errors.
